In a regulatory filing, Cogent Biosciences (COGT) disclosed that its Chief Commercial Officer Cole Pinnow bought 43.8K shares of common stock on January 14th in a total transaction size of $332.4K.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target lowered to $14 from $17 at H.C. Wainwright
- Cogent Biosciences highlighted key 2025 milestones
- Cogent Biosciences downgraded to Hold from Buy at Needham
- Cogent Biosciences announces updates results from SUMMIT
- Cogent Biosciences announces updated data from ongoing Phase 2 APEX trial